Susceptibility and outcome in oral cancer: Preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6

Pharmacogenetics

Volumn 8, Issue 5, 1998, Pages 433-439

  Worrall, Stephen F ^a   Corrigan, Michael ^b   High, Alec ^b   Starr, Don ^b   Matthias, Christoph ^c   Wolf, C Roland ^d   Jones, Peter W ^e   Hand, Philip ^e   Gilford, Janice ^e   Farrell, William E ^e   Hoban, Paul ^e   Fryer, Anthony A ^e   Strange, Richard C ^e  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b LEEDS DENTAL INSTITUTE   (United Kingdom)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e KEELE UNIVERSITY   (United Kingdom)

Author keywords

CYP2D6; Cytochrome P450; Genetic susceptibility; Oral cavity cancer

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER STAGING; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME POLYMORPHISM; FEMALE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 CYP2D6; DISEASE SUSCEPTIBILITY; DRINKING; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NECK; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 7844251183     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199810000-00008     Document Type: Article

References (28)

1. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312:169-170.
2. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 1996; 56:251-253.
3. Caporaso N, Tucker MA, Hoover RN, Hayes RB, Pickle IW, Issaq HJ, et al. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990; 82:1264-1271.
4. Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E, et al. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994; 343:62-63.
5. Elexpuru-Camiruaga J, Buxton N, Kandula V, Dias VS, Campbell D, McIntosh J, et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase, GSTT1 and GSTM1 and cytochrome P450, CYP2D6 loci. Cancer Res 1995; 55:4237-4259.
6. Elwood JM, Pearson JCG, Skippen DH, Jackson SM. Alcohol, smoking, social and occupational factors in the aetiology of cancer of the oral cavity, pharynx and larynx. Int J Cancer 1984; 34:603-612.
7. Hindle I, Downer MC, Speight PM. The epidemiology of oral cancer. Br J Oral Maxillofacial Surg 1996; 34:471-176.
8. Hirvonen A, Husgafvel-Pursianen K, Karjalainen A, Anttila S, Vainio H. Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidem Biomarkers Prevent 1992; 1:485-489.
9. Johnson NW, Warnakulasuriya KAA. Epidemiology of oral cancer in the United Kingdom. Commun Dental Health 1993: 10 (Suppl 1), 13-29.
10. Lear JT, Heagerty AH, Smith A, Bowers B, Payne CR, Smith CA, et al. Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis 1996; 17:1891-1896.
11. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:195-202.
12. Matthias C, Bockmühl U, Jahnke V, Harries LW, Wolf CR, Jones PW, et al. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics 1998a; 8:1-8.
13. Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 1998b; 8:91-100.
14. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1994; 53:2994-2999.
15. Paine MJI, Gilham D, Roberts GCK, Wolf CR. Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems. Arch Biochem Biophys 1996; 328:143-150.
16. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment and prevention. J Natl Cancer Inst 1996; 88:496-509.
17. Rannug A, Alexandrie A-K, Persson I, Ingelman-Sundberg M, Genetic polymorphism of cytochromes 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occupat Environ Med 1995; 37:25-56.
18. Smith G, Stanley LA, Sim K, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surg 1995; 25:27-65.
19. Strange RC, Fryer AA. The glutathione S-transferases: influence of polymorphism on susceptibility to cancer. In: Boffetta P, Caporaso N, Cuzick J, Lang M, Vineis P, editors. Metabolic polymorphisms and cancer. Lyon: IARC Scientific Publications: 1998 (in press).
20. Trizna Z, Clayman GL, Spitz MR, Briggs KL, Goepfert H. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995; 170:499-501.
21. Union Internationale Contre le Cancer. TNM Classification of malignant tumours. Berlin: Springer-Verlag: 1987.
22. Wilhelmsen K, Mirel D, Marder K, Bernstein M, Naini A, Leal SM, et al. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann Neurol 1997; 41:813-817.
23. Wolf CR, Dale Smith CA, Gough AC, Moss JK, Vallis KA, Howard G, et al. Relationship between the debrisoquine polymorphism and cancer susceptibility. Carcinogenesis 1992; 13:1035-1058.
24. Woolgar JA, Scott J, Vaughan KD, Brown JS. Pathological findings in clinically false-negative and false positive neck dissections for oral carcinoma. Ann Royal Coll Surg 1994; 76:237-244.
25. World Health Organization. International classification of diseases, injuries and causes of death. 9th rev ed. Geneva: WHO; 1977.
26. Worrall SF. Oral cancer incidence between 1971 and 1989. Br J Oral Maxillofacial Surg 1995; 33:195.
27. Worrall SF, Corrigan M. An audit of one surgeon's experience of oral squamous cell carcinoma using a computerised malignancy database. Ann Royal Coll Surg 1995; 77:332-336.
28. Zhou LX, Pihlstrom B, Hardwick JP, Park SS, Wrighton SA, Holtzman JL. Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin Pharmacol Ther 1996; 60:191-198.